Sarepta Therapeutics, Inc. financial data

Symbol
SRPT on Nasdaq
Industry
Pharmaceutical Preparations
Location
215 First Street, Suite 415, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AVI BIOPHARMA INC (to 7/12/2012), ANTIVIRALS INC (to 5/12/1998)
Latest financial report
Q1 2024 - May 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 451 % +2.43%
Quick Ratio 52.8 % +45.5%
Debt-to-equity 283 % -36.8%
Return On Equity 2.03 %
Return On Assets 0.53 %
Operating Margin -6.76 % +88.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 94.5 M shares +1.48%
Common Stock, Shares, Outstanding 94.5 M shares +1.45%
Common Stock, Value, Issued 9 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 94 M shares +6.58%
Weighted Average Number of Shares Outstanding, Diluted 99.1 M shares +12.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.4 B USD +43.8%
Revenue from Contract with Customer, Excluding Assessed Tax 1.27 B USD +43.6%
Costs and Expenses 1.5 B USD -4.16%
Operating Income (Loss) -94.8 M USD +83.9%
Nonoperating Income (Expense) 129 M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 34.1 M USD
Income Tax Expense (Benefit) 17.2 M USD +2.83%
Net Income (Loss) Attributable to Parent 16.9 M USD
Earnings Per Share, Basic 0.44 USD/shares
Earnings Per Share, Diluted 0.43 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 427 M USD -51%
Cash, Cash Equivalents, and Short-term Investments 1.69 B USD -15.8%
Accounts Receivable, after Allowance for Credit Loss, Current 379 M USD +69.2%
Inventory, Net 374 M USD +84.3%
Other Assets, Current 83 M USD -53.8%
Assets, Current 2.46 B USD -0.95%
Property, Plant and Equipment, Net 249 M USD +36.3%
Operating Lease, Right-of-Use Asset 126 M USD +104%
Other Assets, Noncurrent 176 M USD +8.63%
Assets 3.22 B USD +5.38%
Accounts Payable, Current 91.5 M USD -14.2%
Employee-related Liabilities, Current 32.1 M USD +15.3%
Accrued Liabilities, Current 283 M USD -18%
Contract with Customer, Liability, Current 112 M USD +66.6%
Liabilities, Current 609 M USD +13.4%
Contract with Customer, Liability, Noncurrent 325 M USD -33%
Operating Lease, Liability, Noncurrent 140 M USD +160%
Other Liabilities, Noncurrent 7.52 M USD +19695%
Liabilities 2.26 B USD -3.57%
Accumulated Other Comprehensive Income (Loss), Net of Tax -691 K USD -64.9%
Retained Earnings (Accumulated Deficit) -4.41 B USD +0.38%
Stockholders' Equity Attributable to Parent 961 M USD +34.9%
Liabilities and Equity 3.22 B USD +5.38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -242 M USD -15.6%
Net Cash Provided by (Used in) Financing Activities 22.1 M USD -78.3%
Net Cash Provided by (Used in) Investing Activities 219 M USD +1651%
Common Stock, Shares Authorized 198 M shares 0%
Common Stock, Shares, Issued 94.5 M shares +1.45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.14 M USD +98.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 443 M USD -50.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.19 M USD +2.35%
Deferred Tax Assets, Valuation Allowance 884 M USD +8.84%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 912 M USD +10.8%
Operating Lease, Liability 159 M USD +117%
Depreciation 42.5 M USD +6.25%
Payments to Acquire Property, Plant, and Equipment 32.4 M USD +242%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 16.6 M USD
Lessee, Operating Lease, Liability, to be Paid 399 M USD +292%
Property, Plant and Equipment, Gross 418 M USD +27.1%
Operating Lease, Liability, Current 17.8 M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 34.5 M USD +66.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 33.7 M USD +60.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12%
Deferred Income Tax Expense (Benefit) -165 K USD +73%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 240 M USD +738%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28 M USD +82.8%
Deferred Tax Assets, Operating Loss Carryforwards 155 M USD -35.9%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 16 M USD +13.5%
Preferred Stock, Shares Authorized 3.33 M shares 0%
Unrecognized Tax Benefits 65 M USD +5.39%
Lessee, Operating Lease, Liability, to be Paid, Year Four 28 M USD +232%
Operating Lease, Payments 21.6 M USD +4%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 11.1 M USD -15.8%
Current Federal Tax Expense (Benefit) 4.18 M USD
Amortization of Intangible Assets 1.98 M USD +178%
Depreciation, Depletion and Amortization 8.74 M USD -22.7%
Share-based Payment Arrangement, Expense 182 M USD -25.8%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 19.9 M USD -54.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%